AstraZeneca Pharma up 3% on receiving import and market permission from DGCI for QTERN

The receipt of this Import and Market permission paves way for the launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN) in India, subject to the receipt of other related statutory approvals and licenses.

from India Infoline News Service https://ift.tt/2nggrxp